181 related articles for article (PubMed ID: 6402934)
1. Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
Bruckner HW; Cohen CJ; Goldberg JD; Kabakow B; Wallach RC; Deppe G; Reisman AZ; Gusberg SB; Holland JF
Am J Obstet Gynecol; 1983 Mar; 145(6):653-8. PubMed ID: 6402934
[TBL] [Abstract][Full Text] [Related]
2. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Vriesendorp R; Kooyman CD; van Lindert AC; Hamerlynck JV; van Lent M; van Houwelingen JC
Lancet; 1984 Sep; 2(8403):594-600. PubMed ID: 6147640
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
4. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
6. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
Edwards CL; Herson J; Gershenson DM; Copeland LJ; Wharton JT
Gynecol Oncol; 1983 Apr; 15(2):261-77. PubMed ID: 6403413
[TBL] [Abstract][Full Text] [Related]
8. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
Greco FA; Johnson DH; Hainsworth JD
Cancer Treat Rev; 1991 Mar; 18 Suppl A():47-55. PubMed ID: 1904309
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
Kane R; Harvey H; Andrews T; Bernath A; Curry S; Dixon R; Gottlieb R; Kukrika M; Lipton A; Mortel R; Ricci J; White D
Cancer Treat Rep; 1979 Feb; 63(2):307-9. PubMed ID: 109201
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin (CHAD) as second-line chemotherapy for ovarian adenocarcinoma.
Piver MS; Lele S; Barlow JJ
Cancer Treat Rep; 1981; 65(1-2):149-51. PubMed ID: 6784921
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
Sessa C; Colombo N; Bolis G; Marsoni S; Mangioni C
Cancer Treat Rev; 1991 Mar; 18 Suppl A():37-46. PubMed ID: 1904308
[No Abstract] [Full Text] [Related]
12. CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
Schwartz PE; Keating G; Kohorn EI; Chambers JT
Gynecol Oncol; 1986 Nov; 25(3):340-6. PubMed ID: 3096820
[TBL] [Abstract][Full Text] [Related]
13. Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
Bruckner HW; Cohen CJ; Feuer E; Holland JF
Obstet Gynecol; 1989 Mar; 73(3 Pt 1):349-56. PubMed ID: 2492648
[TBL] [Abstract][Full Text] [Related]
14. Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
Vogl SE; Pagano M; Kaplan BH; Greenwald E; Arseneau J; Bennett B
Cancer; 1983 Jun; 51(11):2024-30. PubMed ID: 6404547
[TBL] [Abstract][Full Text] [Related]
15. Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.
Bruckner HW; Cohen C; Mandeli J; Chesser MR; Kabakow B; Wallach R; Holland J
Cancer Treat Rev; 1991 Mar; 18 Suppl A():57-65. PubMed ID: 1904310
[TBL] [Abstract][Full Text] [Related]
16. cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Chemother Pharmacol; 1983; 10(2):100-3. PubMed ID: 6403254
[TBL] [Abstract][Full Text] [Related]
17. Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
Razis DV; Poulakou E; Petounis A; Papadimitriou G; Kosmides P; Delides G
Oncology; 1982; 39(4):205-8. PubMed ID: 6806735
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
Bruckner HW; Cohen CJ; Deppe G; Kabakow B; Wallach R; Ratner L; Holland JF
Gynecol Oncol; 1981 Oct; 12(2 Pt 1):150-3. PubMed ID: 6795095
[No Abstract] [Full Text] [Related]
19. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
van der Hoop RG; van der Burg ME; ten Bokkel Huinink WW; van Houwelingen C; Neijt JP
Cancer; 1990 Oct; 66(8):1697-702. PubMed ID: 2119878
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
Omura GA; Morrow CP; Blessing JA; Miller A; Buchsbaum HJ; Homesley HD; Leone L
Cancer; 1983 Mar; 51(5):783-9. PubMed ID: 6401594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]